Skip to content

Exploring the Genetics of Schizophrenia in Manitoba

Uncovering Schizophrenia Genetics Through Whole Genome Sequencing Across Manitoba

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07656870
Acronym
GENES-MB
Enrollment
1500
Registered
2026-06-18
Start date
2026-08-01
Completion date
2031-04-01
Last updated
2026-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy (Controls), Schizophrenia

Keywords

schizophrenia, genetics, saliva, genome, sequencing

Brief summary

Schizophrenia is a serious mental illness that affects about 1 in 100 Canadians, shortens life expectancy, and places a large burden on individuals, families, and the healthcare system. Genetics are known to play a major role, but current research explains only part of the inherited risk because most studies have looked at only a small portion of the genome and have mainly focused on people outside Canada. This project will create the first large-scale Manitoba-based schizophrenia whole-genome sequencing database by studying 1,500 Manitobans with and without schizophrenia using both short-read and advanced long-read genome sequencing technologies. Researchers will combine genetic data with lifelong provincial health records to better understand rare genetic variants linked to schizophrenia and how genetic differences influence medication response, side effects, hospitalizations, and treatment outcomes. The study aims to fill important gaps in schizophrenia research in Canada, improve understanding of the disorder's biology, and support the development of more personalized and effective treatments for people living with schizophrenia.

Detailed description

This study aims to better understand the genetic factors involved in schizophrenia by collecting saliva samples from people with schizophrenia and individuals without psychiatric disorders across Manitoba. Researchers will use advanced genome sequencing to examine differences in genetic variation and identify genes that may contribute to schizophrenia. By combining genetic information with health and clinical data, this research will help improve our understanding of schizophrenia and support the development of more personalized approaches to treatment and care. People with schizophrenia (cases) will be recruited through participating psychosis clinics in Manitoba, review and sign a consent form, provide a saliva sample for genetic testing, allow researchers to use information already collected through the Manitoba Psychosis Registry and link it with health records. People without schizophrenia or other major psychiatric disorders (screened controls) will be screened to ensure they meet eligibility requirements, review and sign a consent form, complete questionnaires about their health, quality of life, and life experiences, provide a saliva sample for genetic testing, allow researchers to link their genetic information with health records. Objective: To understand how genes contribute to schizophrenia and psychosis by analyzing DNA samples from people with and without these conditions. Endpoints: Collection of DNA samples, identification of genetic differences associated with schizophrenia and psychosis, and understanding how these genetic factors relate to symptoms, health outcomes, and disease risk.

Interventions

None listed

Sponsors

University of Manitoba
Lead SponsorOTHER
Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Individuals aged 18 years and older, * Reside in Manitoba, * Involved in the EPPIS, STEP, PACT, ACT/FACTT clinics, * Clinical diagnosis of schizophrenia using standard DSM-5 criteria, * Previously consented and enrolled in the MPR.

Exclusion criteria

* There are no specific

Design outcomes

Primary

MeasureTime frameDescription
Genetic variation associated with schizophreniathrough study completion, an average of 1 yearIdentification of rare and common genetic variants through short-read and long-read whole genome sequencing. Comparison of genetic variant burden between schizophrenia cases and controls.
Rare variant burden in schizophreniathrough study completion, an average of 1 yearEvaluation of the frequency and distribution of rare genetic variants in individuals with schizophrenia compared with controls.
Pharmacogenetic associationsthrough study completion, an average of 1 yearIdentification of genetic variants associated with antipsychotic treatment response and adverse drug reactions.

Countries

Canada

Contacts

CONTACTKaarina Kowalec, PhD
kaarina.kowalec@umanitoba.ca204-619-5711

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 19, 2026